BioCardia CEO buys 5,400 shares in open market

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share.

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share. Following this transaction, he directly owns 361,985 shares. The trades were executed in multiple lots between $0.92 and $1.05 per share.

Insider Trade Summary

Net Buyer: 5,400 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,400 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,400	$0.9645	$5K

Holdings After Transaction: Common Stock — 361,985 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades ranging from $0.92 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased: 5,400 shares Weighted average price: $0.9645 per share Post-transaction holdings: 361,985 shares +2 more

5 metrics

Shares purchased 5,400 shares Open-market purchase of Common Stock

Weighted average price $0.9645 per share Price for 5,400-share purchase

Post-transaction holdings 361,985 shares Direct ownership after transaction

Trade price range $0.92–$1.05 per share Range of prices for multiple trade lots

Net buy shares 5,400 shares Net change in non-derivative position

Key Terms

open-market purchase, weighted average price, Common Stock, multiple trades

4 terms

open-market purchase financial

"an open-market purchase of 5,400 shares of Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"at a weighted average price of $0.9645 per share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"open-market purchase of 5,400 shares of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

multiple trades financial

"transaction was executed in multiple trades ranging from $0.92 to $1.05"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported an open-market purchase of 5,400 BioCardia Common Stock shares. The weighted average price was $0.9645 per share, and the trades occurred in multiple lots between $0.92 and $1.05, increasing his direct holdings to 361,985 shares.

At what prices did the BioCardia (BCDA) CEO’s share purchases occur?

The CEO’s 5,400-share purchase was executed in multiple trades ranging from $0.92 to $1.05 per share. The Form 4 reports a weighted average price of $0.9645 per share for the transaction, reflecting the combined pricing across all trade lots.

How many BioCardia (BCDA) shares does the CEO hold after this transaction?

After this reported purchase, Peter Altman directly holds 361,985 shares of BioCardia Common Stock. This total reflects his position following the acquisition of 5,400 shares in an open-market transaction at a weighted average price of $0.9645 per share.

What type of insider transaction is reported for BioCardia (BCDA)?

The reported transaction is an open-market purchase of Common Stock by the CEO. It is coded as “P” on Form 4, indicating a purchase in the open market or private transaction, rather than an option exercise, gift, or tax-withholding event.

Does the BioCardia (BCDA) Form 4 disclose how the insider trade was executed?

Yes. The filing states the purchase was executed in multiple trades within a $0.92 to $1.05 per-share range. The Form 4 reports a single weighted average price of $0.9645 and notes full trade details are available upon request to the company, SEC staff, or security holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 03:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		P		5,400(1)	A	$0.9645(1)	361,985	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.92 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)